Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compared to conventional treatment strategies. With concerns of the inadequate use of thrombolysis in patients with STEMI in China, this study applies a new artificial intelligence assisted mobile application to guide the process of thrombolysis combined with PCI treatment, in order to accomplish the rapid coordination and cooperation of the whole medical network during re-perfusion treatment in different regions and different medical institutions in China, increases the proportion of early thrombolysis in pre-hospital setting, shortens the time from STEMI onset to reperfusion, and provides a reliable, effective and replicable new strategy for promoting and optimizing early reperfusion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Comprehensive promotion group | Experimental | A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc. |
|
| Control group | No Intervention | Patients in the control group will be tranferred and managed according to the existing model |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| A novel artificial intelligence assisted mobile application | Other | A novel artificial intelligence assisted mobile application will be used in the experimental group to guide entire reperfusion process in patients with STEMI. The functions of the application include patient screening, education and training, route planning for patient transfer, time management, and quality control, etc.The thrombolytic drug used in this study is tenecteplase (manufacturer: CSPC Pharmaceutical Group Limited, China ). |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of major adverse events (MAEs) at 1 year | Incidence of major adverse events (MAEs) at 1 year. MAE is a composite endpoint that includes all-cause mortality, stroke, cardiogenic shock, rehospitalization for ischemic heart failure, or reinfarction. | Day 365 |
| Measure | Description | Time Frame |
|---|---|---|
| Total ischemic time before reperfusion | Day 30 | |
| Total reperfusion rate during therapeutic time window | Hour 48 | |
| The proportion of ECG ST segment resolution(STR) ≥ 70% after thrombolysis or emergency PCI |
Not provided
Inclusion Criteria:
(the following inclusion conditions shall be met at the same time):
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kai Xu, MD,PhD | Contact | +8615309880917 | xukai2001@sina.com |
| Name | Affiliation | Role |
|---|---|---|
| Yaling Han, MD,PhD | Northern Theater Command General Hospital of the People's Liberation Army | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| No. 83, Wenhua Road, Shenhe District, Shenyang City | Recruiting | Shenyang | Liaoning | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000072657 | ST Elevation Myocardial Infarction |
| D009203 | Myocardial Infarction |
| ID | Term |
|---|---|
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D014652 | Vascular Diseases |
Not provided
Not provided
Multi-center, cluster randomized controlled trial
Not provided
Not provided
Not provided
Not provided
|
| Hour 48 |
| Proportion of TIMI blood flow grade 3 before emergency PCI | Hour 48 |
| Proportion of TIMI blood flow grade 3 after emergency PCI | Hour 48 |
| Incidence of 30-day MAEs | MAE is a composite endpoint that includes all-cause mortality, stroke, cardiogenic shock, rehospitalization for ischemic heart failure, or reinfarction. | Day 30 |
| Incidence of major adverse cardiac events (MACE) at 1 year | MACE is a composite endpoint including cardiac death, reinfarction, clinically-driven revascularization, ischemic cardiomyopathy, or myocardial ischemia-driven rehospitalization | Day 365 |
| D007238 |
| Infarction |
| D007511 | Ischemia |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009336 | Necrosis |